**Alto Neuroscience (NYSE:ANRO) Enters into Amended Loan Agreement with K2 HealthVentures LLC**Alto Neuroscience, Inc. (ANRO) recently disclosed its current report, Form 8-K filing to the Securities and Exchange Commission. The filing, dated January
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Alto Neuroscience’s 8K filing here. About Alto Neuroscience (Get Free Report) Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in […]
More Stories
Mirador Capital Partners LP Purchases 1,319 Shares of KKR & Co. Inc. (NYSE:KKR)
Mirador Capital Partners LP grew its position in KKR & Co. Inc. (NYSE:KKR – Free Report) by 1.4% during the...
Hennion & Walsh Asset Management Inc. Sells 226 Shares of S&P Global Inc. (NYSE:SPGI)
Hennion & Walsh Asset Management Inc. cut its stake in shares of S&P Global Inc. (NYSE:SPGI – Free Report) by...
RMR Wealth Builders Purchases 189 Shares of S&P Global Inc. (NYSE:SPGI)
RMR Wealth Builders boosted its holdings in S&P Global Inc. (NYSE:SPGI – Free Report) by 6.6% during the 4th quarter,...
iShares Russell 2000 Value ETF (NYSEARCA:IWN) Sees Strong Trading Volume – Still a Buy?
iShares Russell 2000 Value ETF (NYSEARCA:IWN – Get Free Report) shares saw an uptick in trading volume on Thursday ....
PayPal (NASDAQ:PYPL) Given New $80.00 Price Target at Wells Fargo & Company
PayPal (NASDAQ:PYPL – Get Free Report) had its price objective hoisted by stock analysts at Wells Fargo & Company from...
BlackRock (NYSE:BLK) Given New $1,175.00 Price Target at Wells Fargo & Company
BlackRock (NYSE:BLK – Get Free Report) had its target price hoisted by equities researchers at Wells Fargo & Company from...